Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-01-01 @ 3:52 AM
Study NCT ID:
NCT05234905
Status:
UNKNOWN
Last Update Posted:
2022-02-10
First Post:
2022-01-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
H101 Combined With Camrelizumab for Recurrent Cervical Cancer
Sponsor:
Zhejiang Cancer Hospital
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03
Start Date Type:
ESTIMATED
Primary Completion Date:
2023-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-12
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-27
First Submit QC Date:
None
Study First Post Date:
2022-02-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-08
Last Update Post Date:
2022-02-10
Last Update Post Date Type:
ACTUAL